SERUM ANTIBODY ASSAY FOR DETERMINING PROTECTION FROM MALARIA, AND PRE-ERYTHROCYTIC SUBUNIT VACCINES
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
N/A
Issued Date -
Jul 28, 2016
app pub date -
Sep 2, 2014
filing date -
Aug 30, 2013
priority date (Note) -
Abandoned
status (Latency Note)
Importance
Abstract
Disclosed herein are diagnostic assays for identifying individuals that are protected against Plasmodium falciparum caused malaria. Such assays are particularly useful for determining not only the protective efficacy of Pf whole parasite vaccines for individual subjects, but also within populations of vaccinated subjects. The assays comprise the use of proteomes representing at least 50% of Pf, preferably coupled to a solid phase as a fixed array. The arrays are used to probe the sera of human subjects, particularly subjects of human clinical trials of whole parasite malaria vaccines as well as public health vaccination campaigns. Serum samples with antibody profiles most strongly reactive in multiplex to CSP and MSP5 demonstrate a sensitivity of from 92% to 100% and a specificity of from 84% to 89%.
First Claim
Family
International Classification(s)
- [Classification Symbol]
- [Patents Count]
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully